KATHERA BIOSCIENCE INC.
Biotech · Private
Small molecule DHFR inhibitors for systemic fungal infections
- Grants
- $3.2M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Ess1: A pathogenic fungal target for a novel class of broad-spectrum therapeutic agents | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase I · A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase I · A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections | $298,530 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens | $995,100 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens | $995,100 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2708 | Alltrna | — | — |
| 2709 | THYREOS, INC | — | — |
| 2710 | ISOPRENE PHARMACEUTICALS, INC. | — | — |
| 2711 | KATHERA BIOSCIENCE INC. | — | — |
| 2712 | ENCUE INC. | — | — |
| 2713 | Immune Response BioPharma, Inc. | — | $1.0B |
| 2714 | Foghorn Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.